ADMS
Adamas Pharmaceuticals
ADMS
ADMS
Delisted
ADMS was delisted on the 23rd of November, 2021.
64 hedge funds and large institutions have $61.9M invested in Adamas Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
45% less call options, than puts
Call options by funds: $61K | Put options by funds: $111K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
64
Holding in Top 10
–
Calls
$61K
Puts
$111K
Top Buyers
| 1 | +$3.5M | |
| 2 | +$1.37M | |
| 3 | +$796K | |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$654K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$422K |
Top Sellers
| 1 | -$2.65M | |
| 2 | -$2.3M | |
| 3 | -$1.27M | |
| 4 |
DAM
Deltec Asset Management
New York
|
-$478K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$223K |